OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Recent Advances in Treatment of Acute Myeloid Leukemia

home / peer-exchange / treatment-of-acute-myeloid-leukemia
Molecular Testing for AML

EP. 1: Molecular Testing for AML

January 28th 2020
AML Induction Strategy and Molecular Testing

EP. 2: AML Induction Strategy and Molecular Testing

January 28th 2020
Assessment of Fitness for AML Induction Chemotherapy

EP. 3: Assessment of Fitness for AML Induction Chemotherapy

January 28th 2020
Decision Making on Consolidation Therapy for AML

EP. 4: Decision Making on Consolidation Therapy for AML

January 28th 2020
QUAZAR: Oral Azacitidine Maintenance in AML

EP. 5: QUAZAR: Oral Azacitidine Maintenance in AML

January 28th 2020
Hypomethylating Agents for AML

EP. 6: Hypomethylating Agents for AML

January 28th 2020
Venetoclax-Based Regimens for Unfit Patients with AML

EP. 7: Venetoclax-Based Regimens for Unfit Patients with AML

January 28th 2020
Managing Venetoclax-Associated Toxicity in AML

EP. 8: Managing Venetoclax-Associated Toxicity in AML

January 28th 2020
Venetoclax-Based Chemotherapy Combinations in AML

EP. 9: Venetoclax-Based Chemotherapy Combinations in AML

January 28th 2020
CPX-351 for Secondary AML

EP. 10: CPX-351 for Secondary AML

January 28th 2020
Previously Untreated FLT3-Mutated AML

EP. 11: Previously Untreated FLT3-Mutated AML

January 28th 2020
Second-Generation FLT3 Inhibitors for AML

EP. 12: Second-Generation FLT3 Inhibitors for AML

January 28th 2020
Relapsed/Refractory FLT3-Mutated AML

EP. 13: Relapsed/Refractory FLT3-Mutated AML

January 28th 2020
IDH1/2 Inhibitors in AML

EP. 14: IDH1/2 Inhibitors in AML

January 28th 2020
Differentiation Syndrome and IDH1/2 Inhibitors

EP. 15: Differentiation Syndrome and IDH1/2 Inhibitors

January 28th 2020
Gemtuzumab Ozogamicin for CD33+ AML and APL

EP. 16: Gemtuzumab Ozogamicin for CD33+ AML and APL

January 28th 2020
Immune Checkpoint Inhibitors for AML

EP. 17: Immune Checkpoint Inhibitors for AML

January 28th 2020
Novel Agents Under Investigation for AML

EP. 18: Novel Agents Under Investigation for AML

January 28th 2020

Latest Conference Coverage

Real-World Data Confirm Efficacy of Axi-cel Across Patient-Related Factors in R/R LBCL

Bexobrutideg Is Safe, Shows Early Efficacy in Relapsed/Refractory CLL

Asciminib Shows Superior Tolerability Over Nilotinib in Newly Diagnosed CML in Chronic Phase

ESAs or Danazol Plus Ruxolitinib Produce Comparable Spleen and Symptom Response Rates in Myelofibrosis With Anemia

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact